MicroQuin received support from the United States Department of War Congressionally Directed Medical Research Programs (CDMRP) for supporting research on ovarian cancer and the Ovarian Cancer Research Program.
Public source
Publisher name
Public post
What if cancer's greatest weakness could be cancer itself? This video shows ovarian cancer cells (SK-OV-3) undergoing paraptosis, a unique form of programmed cell death,…
Company
MicroQuin
Revolutionizing Disease/Injury treatment by controlling the Intracellular Environment (ICE)
- Industry
- Biotechnology
- Location
- Cambridge, US
- Company size
- 2–10 employees
About MicroQuin
Disease begins inside the cell. So does the solution. At the core of all disease is intracellular environmental change (ICE). MicroQuin have small molecules that can modulate the ICE to slow, stop or reverse disease/injury.
See moreLatest activity
Latest activity from MicroQuin
6 signals
Research & Knowledge
MicroQuin published a recent Oncogene publication describing how TMBIM6/BI-1 regulates pathways leading to paraptotic cell death in cancer cells.
Research & Knowledge
MicroQuin received support from the United States Department of War CDMRP for research on TMBIM6 structural data in microgravity.
Research & Knowledge
MicroQuin derived TMBIM6 structural data in a microgravity environment using NASA, Boeing, and the International Space Station National Laboratory.
Discover more
Similar signals
Similar public activity from other companies.
Partnerships
Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. entered into a Collaborative Research and Development Agreement with the National Cancer Institute to study the efficacy, mechanism of action, and immune response associated with Intensity’s intratumoral approach.
Partnerships
Migration Biotherapeutics Limited
Migration Biotherapeutics Limited and National Physical Laboratory (NPL) have collaborated to develop a materials-based platform to treat lethal cancers including Glioblastoma.
Partnerships
BioFire Defense
BioFire Defense is the sole supplier of the BIOFIRE portfolio of multiplex PCR diagnostic tests to the United States Department of War and other U.S. Government Agencies.
Partnerships
Lytix Biopharma
Lytix Biopharma is looking to connect with investors and strategic partners to advance next-generation oncology treatments.
Partnerships
enGene